Curis vs Eloxx Pharmaceuticals
CRIS and ELOX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and ELOX compare
Eloxx Pharmaceuticals is the larger company, worth 57 times as much as Curis ($51.5M against $911K).
Curis grew revenue faster over the last twelve months (−62.2% versus −100% for Eloxx Pharmaceuticals).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | ELOX |
|---|---|---|
| Size and price | ||
| Market cap | $911K | $51.5M |
| Share price | $0.436 | $12.75 |
| Change, 1 year | −98.1% | 1158990% |
| Change, 5 years | −100.0% | −97.9% |
| Beta (5Y) | 0.24 | – |
| Employees | 24 | 7 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× | – |
| P/B | 0.2× (better) | 1.1× |
| Fair value | $6.86 | – |
| Margin of safety | 93.6% | – |
| Growth | ||
| Revenue growth (TTM) | −62.2% (better) | −100% |
| Revenue growth, 5Y average | −2.7% | – |
| Profitability | ||
| Operating margin | −203% | – |
| Net margin | −490% | – |
| Return on equity | – | −54.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.49 | 3.74 (better) |
| Altman Z-score | −96.18 | −4.46 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | −2700% | 0.00% (better) |
| Shareholder yield | −2700% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 32.1% | 71.8% |
| Held by insiders | 20.4% | 42.6% |
| Insider net buying, 12 months | $5.5K | – |
| Short interest, % of float | 61.8% | 2.3% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.